By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Novartis has signed a definitive agreement to acquire personalized diagnostics lab services firm Genoptix for approximately $470 million.

Novartis will pay $25 per share in cash for all of the outstanding shares of the Carlsbad, Calif.-based company. The purchase price represents an approximately 27 percent premium to Genoptix's Friday closing price on the Nasdaq of $19.76.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.